Lesser Known Lung Cancer Mutations Part 1: HER2, a promising therapeutic target?


By now, most patients (and hopefully, all oncologists!) are familiar with the significance of EGFR mutations in non-small cell lung cancer (NSCLC). The discovery of ALK mutations and the successful use of crizotinib in this setting has also been big news in the lung cancer world. I'd like to bring everyone up to date on two lesser known abnormalities that can occur in non-small cell lung cancer: HER2 and BRAF mutations.

Subscribe to HER2